ESTRO 2024 - Abstract Book

S2489

Clinical - Urology

ESTRO 2024

Conclusion:

In our retrospective review of 581 prostate cancer patients who received leuprolide, over 50% achieved testosterone recovery, with a median TTR of 6.3 months. We found that diabetes/prediabetes and obesity were risk factors for non-recovery of testosterone to normal levels after cessation of ADT. As BMI and diagnosis of diabetes may not truly assess for underlying metabolic dysfunction, our future goal is to assess for visceral adiposity using imaging to further evaluate its impact on testosterone recovery. Moreover, larger multi-institutional datasets are needed to confirm these findings, especially with careful examination of diet and exercise, in order to help better inform patients on risk factors that impact the probability of testosterone recovery.

Keywords: ADT, testosterone recovery, prostate cancer

References:

1. Long ME, Vitale AM, Mott SL, et al: Decreased testosterone recovery after androgen deprivation therapy for prostate cancer. Can J Urol 28:10738 – 10742, 2021

2. Murthy V, Norman AR, Shahidi M, et al: Recovery of serum testosterone after neoadjuvant androgen deprivation therapy and radical radiotherapy in localized prostate cancer. BJU Int 97:476 – 479, 2006

3. Padula GDA, Zelefsky MJ, Venkatraman ES, et al: Normalization of serum testosterone levels in patients treated with neoadjuvant hormonal therapy and three-dimensional conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 52:439 – 443, 2002

4. Nam W, Choi SY, Yoo SJ, et al: Factors associated with testosterone recovery after androgen deprivation therapy in patients with prostate cancer. Investig Clin Urol 59:18 – 24, 2018

5. Nejat RJ, Rashid HH, Bagiella E, et al: A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy. J Urol 164:1891 – 1894, 2000

2015

Digital Poster